Literature DB >> 29774318

Biological Subtypes of Breast Cancer and Sentinel Lymph Node Biopsy.

Muhammet Kadri Çolakoğlu1, Erhan Güven2, Gökhan Giray Akgül3, Lütfi Doğan4, Mehmet Ali Gülçelik2.   

Abstract

OBJECTIVE: Breast cancer subtypes are used as prognostic and predictive factors considering the genomic profile of the disease. This study is designed to investigate the Sentinel Lymph Node (SLN) detection rate in breast cancer for different biological characteristics.
MATERIAL AND METHODS: Patients on whom we performed the methylene blue method alone were named as Group I, radiocolloid substance method alone as Group II and both methylene blue and radiocolloid method as Group III. The results of biological tumor characteristics and characteristics of the patients on different SLN biopsy techniques were investigated.
RESULTS: The overall SLN detecting success rate was 83.3%. When considered for each group, success rate was 80% for group I, 84.9% for group II and 90.6% for group III. While a success rate of 94.6% was achieved with radiocolloid only in the patients in Luminal A and B subgroup, 90% success rate was achieved in Her2 (+) and triple negative (TN) patients with combined method.
CONCLUSION: While successful results could be achieved by using radiocolloid substances alone in patients with Luminal A and B subtypes, combined methods should be used in HER2 (+) and TN patients.

Entities:  

Keywords:  Breast cancer; methylene blue; radiocolloid; sentinel lymph node biopsy

Year:  2018        PMID: 29774318      PMCID: PMC5939972          DOI: 10.5152/ejbh.2018.3780

Source DB:  PubMed          Journal:  Eur J Breast Health


  22 in total

1.  Lessons learned from 500 cases of lymphatic mapping for breast cancer.

Authors:  A D Hill; K N Tran; T Akhurst; H Yeung; S D Yeh; P P Rosen; P I Borgen; H S Cody
Journal:  Ann Surg       Date:  1999-04       Impact factor: 12.969

2.  Factors predicting failure to identify a sentinel lymph node in breast cancer.

Authors:  Anees B Chagpar; Robert C Martin; Charles R Scoggins; David J Carlson; Alison L Laidley; Souzan E El-Eid; Terre Q McGlothin; Robert D Noyes; Phillip B Ley; Todd M Tuttle; Kelly M McMasters
Journal:  Surgery       Date:  2005-07       Impact factor: 3.982

3.  Factors of importance for scintigraphic non-visualisation of sentinel nodes in breast cancer.

Authors:  A H Chakera; E Friis; U Hesse; N Al-Suliman; B Zerahn; B Hesse
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-10-05       Impact factor: 9.236

4.  Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes.

Authors:  U Veronesi; G Paganelli; V Galimberti; G Viale; S Zurrida; M Bedoni; A Costa; C de Cicco; J G Geraghty; A Luini; V Sacchini; P Veronesi
Journal:  Lancet       Date:  1997-06-28       Impact factor: 79.321

5.  The impact of dynamic lymphoscintigraphy and gamma probe guidance on sentinel node biopsy in melanoma.

Authors:  R Pijpers; G J Collet; S Meijer; O S Hoekstra
Journal:  Eur J Nucl Med       Date:  1995-11

6.  Sentinel lymph node biopsy for breast cancer: the role of previous biopsy on patient eligibility.

Authors:  T J Miner; C D Shriver; D P Jaques; M E Maniscalco-Theberge; D N Krag
Journal:  Am Surg       Date:  1999-06       Impact factor: 0.688

7.  Age and body mass index may increase the chance of failure in sentinel lymph node biopsy for women with breast cancer.

Authors:  Charles E Cox; Elisabeth Dupont; George F Whitehead; Mark D Ebert; Keoni Nguyen; Eric S Peltz; Darian Peckham; Alan Cantor; Douglas S Reintgen
Journal:  Breast J       Date:  2002 Mar-Apr       Impact factor: 2.431

8.  Sentinel node detection using 99mTc-rhenium sulphide colloid in breast cancer patients: evaluation of 1 day and 2 day protocols, and a dose-finding study.

Authors:  M Koizumi; E Nomura; Y Yamada; T Takiguchi; K Tanaka; M Yoshimoto; M Makita; G Sakamoto; F Kasumi; E Ogata
Journal:  Nucl Med Commun       Date:  2003-06       Impact factor: 1.690

9.  Role of patient and tumor characteristics in sentinel lymph node metastasis in patients with luminal early breast cancer: an observational study.

Authors:  Nicla La Verde; Elena Biagioli; Chiara Gerardi; Andrea Cordovana; Chiara Casiraghi; Irene Floriani; Elena Bernardin; Gabriella Farina; Serena Di Cosimo; Maria Chiara Dazzani; Giorgio Gherardi
Journal:  Springerplus       Date:  2016-02-03

Review 10.  The combination of blue dye and radioisotope versus radioisotope alone during sentinel lymph node biopsy for breast cancer: a systematic review.

Authors:  Pei-Sheng He; Feng Li; Guan-Hua Li; Can Guo; Tian-Jin Chen
Journal:  BMC Cancer       Date:  2016-02-16       Impact factor: 4.430

View more
  1 in total

Review 1.  The Adventure of Axillary Treatment in Early Stage Breast Cancer.

Authors:  Bekir Kuru
Journal:  Eur J Breast Health       Date:  2020-01-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.